Product Information
ALLOPURINOL 300 MG TABLET is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.0522 per EA under NDC 16571088509. Its NADAC has been published 100 times since Nov 6, 2024.
FDA first approved this application before 1982. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the allopurinol market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
300 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
16571088509
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ALLOPURINOLApproval Type
Authorized Generic (NDA)
FDA Application
NDA016084FDA Approved
Before 1982
TE Code
AB
On Market Since
9/21/2023
Pharmacological Classes
Price Statistics
The NADAC for ALLOPURINOL 300 MG TABLET has been published 100 times since Nov 6, 2024, and over the history we have for it it has declined 23.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0522 per EA |
|---|---|
| All-time high | $0.0690 (Apr 16, 2025) |
| All-time low | $0.0522 (Sep 23, 2026) |
| 52-week high | $0.0652 |
| 52-week low | $0.0522 |
| Median price | $0.0630 |
| Average price | $0.0619 |
| Largest weekly change | -17.0% (Nov 20, 2024) |
| Weeks tracked | 100 |
| Tracking since | Nov 6, 2024 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
allopurinol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Xanthine Oxidase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ALLOPURINOL 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ALLOPURINOL 300 MG TABLET, manufactured by Rising Pharma Holdings Inc., is $0.0522 per EA (NDC 16571088509), effective Sep 30, 2026.
How has the price of ALLOPURINOL 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for ALLOPURINOL 300 MG TABLET has declined 23.8%. It has been tracked across 100 weekly CMS publications since Nov 6, 2024.
What are the highest and lowest recorded NADAC prices for ALLOPURINOL 300 MG TABLET?
Since Nov 6, 2024, the NADAC for ALLOPURINOL 300 MG TABLET has ranged from a low of $0.0522 (Sep 23, 2026) to a high of $0.0690 (Apr 16, 2025), with a median of $0.0630 per EA.
Are there cheaper alternatives to ALLOPURINOL 300 MG TABLET?
6 manufacturers publish a NADAC-priced product with the same active ingredient and strength as ALLOPURINOL 300 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures ALLOPURINOL 300 MG TABLET?
ALLOPURINOL 300 MG TABLET (NDC 16571088509) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.